Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jan;67(1):94-103.
doi: 10.1111/aas.14145. Epub 2022 Sep 12.

Markers of neutrophil mediated inflammation associate with disturbed continuous electroencephalogram after out of hospital cardiac arrest

Affiliations
Observational Study

Markers of neutrophil mediated inflammation associate with disturbed continuous electroencephalogram after out of hospital cardiac arrest

Pirkka T Pekkarinen et al. Acta Anaesthesiol Scand. 2023 Jan.

Abstract

Background: Achieving an acceptable neurological outcome in cardiac arrest survivors remains challenging. Ischemia-reperfusion injury induces inflammation, which may cause secondary neurological damage. We studied the association of ICU admission levels of inflammatory biomarkers with disturbed 48-hour continuous electroencephalogram (cEEG), and the association of the daily levels of these markers up to 72 h with poor 6-month neurological outcome.

Methods: This is an observational, post hoc sub-study of the COMACARE trial. We measured serum concentrations of procalcitonin (PCT), high-sensitivity C-reactive protein (hsCRP), osteopontin (OPN), myeloperoxidase (MPO), resistin, and proprotein convertase subtilisin/kexin type 9 (PCSK9) in 112 unconscious, mechanically ventilated ICU-treated adult OHCA survivors with initial shockable rhythm. We used grading of 48-hour cEEG monitoring as a measure for the severity of the early neurological disturbance. We defined 6-month cerebral performance category (CPC) 1-2 as good and CPC 3-5 as poor long-term neurological outcome. We compared the prognostic value of biomarkers for 6-month neurological outcome to neurofilament light (NFL) measured at 48 h.

Results: Higher OPN (p = .03), MPO (p < .01), and resistin (p = .01) concentrations at ICU admission were associated with poor grade 48-hour cEEG. Higher levels of ICU admission OPN (OR 3.18; 95% CI 1.25-8.11 per ln[ng/ml]) and MPO (OR 2.34; 95% CI 1.30-4.21) were independently associated with poor 48-hour cEEG in a multivariable logistic regression model. Poor 6-month neurological outcome was more common in the poor cEEG group (63% vs. 19% p < .001, respectively). We found a significant fixed effect of poor 6-month neurological outcome on concentrations of PCT (F = 7.7, p < .01), hsCRP (F = 4.0, p < .05), and OPN (F = 5.6, p < .05) measured daily from ICU admission to 72 h. However, the biomarkers did not have independent predictive value for poor 6-month outcome in a multivariable logistic regression model with 48-hour NFL.

Conclusion: Elevated ICU admission levels of OPN and MPO predicted disturbances in cEEG during the subsequent 48 h after cardiac arrest. Thus, they may provide early information about the risk of secondary neurological damage. However, the studied inflammatory markers had little value for long-term prognostication compared to 48-hour NFL.

Keywords: cardiac arrest; continuous electroencephalogram; hypoxia; inflammation; ischemia; neutrophilic granulocyte; postcardiac arrest syndrome; prognostication; reperfusion injury; seizures.

PubMed Disclaimer

Conflict of interest statement

Giuseppe Ristagno has served at data monitoring committee for DSMB trial: TRansfusion Strategies in Acute Brain INjured Patients (TRAIN).

Kaj Blennow has received consulting fees from Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Lilly, MagQu, Prothena, Roche Diagnostics and Siemens Healthineers; honoraria for lectures from: GEECD/Roche Diagnostics and IFCC/SNIBE; has served at data monitoring committees for: Julius Clinical and Novartis and he is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.

Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.

Jussi Toppila has received consulting/lecture fees from: UCB Pharma Finland and SGS Fimko Ltd.

Figures

FIGURE 1
FIGURE 1
ICU admission biomarker concentrations in relation to poor grade continuous EEG (cEEG) recording of the first 48 h after OHCA. cEEG recording was graded as suggested by Crepeau et al.; we defined grade 1 as good cEEG result (open circles, N = 71), and grade 2 (N = 7) and grade 3 (N = 31) as poor cEEG result (closed circles). Mean values (circles) with SD (error bars) calculated from the ln transformed data are presented. Note the logarithmic scale. *Statistically significant at the p < .05 level. **Statistically significant at the p < .01 level. EEG, electroencephalogram; hsCRP, high‐sensitivity C‐reactive protein; MPO, myeloperoxidase; OPN, Osteopontin; PCT, Procalcitonin; PCSK9, Proprotein convertase subtilisin/kexin type 9
FIGURE 2
FIGURE 2
Biomarker concentrations in 6‐month neurological outcome groups. Violin plots with median (thick line) and IQR (thin lines) are presented. Note the logarithmic scale. ICU adm., ICU admission; Good neurological outcome, 6‐month Cerebral Performance Categories (CPC) 1–2; Poor outcome, 6‐month CPC 3–5. *Statistically significant at the p < .05 level. **Statistically significant at the p < .01 level. hsCRP, high‐sensitivity C‐reactive protein; MPO, myeloperoxidase; OPN, Osteopontin; PCT, Procalcitonin; PCSK9, Proprotein convertase subtilisin/kexin type 9

References

    1. Gräsner JT, Herlitz J, Tjelmeland IBM, et al. European resuscitation council guidelines 2021: epidemiology of cardiac arrest in europe. Resuscitation. 2021;161:61‐79. doi:10.1016/j.resuscitation.2021.02.007 - DOI - PubMed
    1. Nolan JP, Sandroni C, Böttiger BW, et al. European resuscitation council and european society of intensive care medicine guidelines 2021: post‐resuscitation care. Resuscitation. 2021;161:220‐269. doi:10.1016/j.resuscitation.2021.02.012 - DOI - PubMed
    1. Mai N, Miller‐Rhodes K, Knowlden S, Halterman MW. The post‐cardiac arrest syndrome: a case for lung‐brain coupling and opportunities for neuroprotection. J Cereb Blood Flow Metab. 2019;39:939‐958. doi:10.1177/0271678x19835552 - DOI - PMC - PubMed
    1. Hirano Y, Aziz M, Yang WL, et al. Neutralization of osteopontin attenuates neutrophil migration in sepsis‐induced acute lung injury. Crit Care. 2015;19:53. doi:10.1186/s13054-015-0782-3 - DOI - PMC - PubMed
    1. Carbone F, Bonaventura A, Montecucco F. Neutrophil‐related oxidants drive heart and brain remodeling after ischemia/reperfusion injury. Front Physiol. 2019;10:1587. doi:10.3389/fphys.2019.01587 - DOI - PMC - PubMed

Publication types